Study | Region/ country | Study years | Survival [n/N (%)] by gestational age (week) | ||||
22 | 23 | 24 | 25 | Total | |||
Bell*[1] | 19 NRN sites, United States | 2013 to 2018 | Entire cohort: 60/549 (11) | Entire cohort: 535/1083 (49) | Entire cohort: 972/1391 (70) | Entire cohort: 1266/1599 (79) | Entire cohort: 2833/4622 (61) |
AT only: 60/200 (30) | AT only: 535/958 (56) | AT only: 972/1362 (71) | AT only: 1266/1584 (80) | AT only: 2833/4104 (69) | |||
Shah*[2] | Canada | 2010 to 2017 | 27/85 (32) | 339/679 (50) | 1040/1504 (69) | 1681/2067 (81) | 3114/4335 (72) |
Humburg*[3] | Germany | 2011 to 2016 | 60/105 (57) | 355/576 (62) | 868/1165 (75) | 1012/1217 (90) | 2295/3063 (75) |
NEPS2¶[4] | Norway | 2013 to 2014 | 3/17 (18) | 12/42 (29) | 35/62 (56) | 59/70 (84) | 109/191 (57) |
Stoll*[5] | 26 NRN sites, United States | 2012 | 7/75 (9) | 50/150 (33) | 174/269 (65) | 249/308 (81) | 480/802 (60) |
EPIPAGE-2Δ[6] | 26 regions in France | 2011 | 0/58 (0) | 1/89 (1) | 58/186 (31) | 182/308 (59) | 241/641 (38) |
Anderson¶[7] | State of California | 2007 to 2011 | 29/450 (6) | 162/602 (27) | 458/766 (60) | 621/796 (78) | 1270/2614 (49) |
Rysavy[8] | 24 NRN sites, United States | 2006 to 2011 | Entire cohort: 79/357 (5) | Entire cohort: 181/755 (24) | Entire cohort: 634/1152 (55) | Entire cohort: 919/1277 (72) | Entire cohort: 1813/3541 (51) |
AT only: 18/79 (23) | AT only: 179/542 (33) | AT only: 638/1119 (57) | AT only: 905/1257 (72) | AT only: 1740/2997 (58) | |||
Field*[9,10] | Trent, United Kingdom | 2006 to 2010 | 0/1 (0) | 16/80 (20) | 66/151 (44) | 137/204 (67) | 219/436 (50) |
2000 to 2005 | 0/9 (0) | 12/65 (18) | 82/198 (41) | 142/229 (63) | 236/497 (47) | ||
1994 to 1999 | 0/15 (0) | 15/81 (19) | 40/165 (24) | 119/229 (52) | 174/490 (36) | ||
Carlo[11] | 23 NRN sites, United States | 1993 to 2009 | ANS: 32/118 (27) | ANS: 480/1147 (42) | ANS: 1799/2976 (60) | ANS: 2721/3555 (77) | ANS: 5032/7796 (64) |
No ANS: 50/283 (18) | No ANS: 225/831 (27) | No ANS: 399/814 (49) | No ANS: 528/804 (66) | No ANS: 1202/2732 (44) | |||
EXPRESS◊[12] | Sweden | 2004 to 2007 | 5/51 (10) | 53/101 (53) | 96/144 (67) | 167/205 (81) | 321/501 (64) |
Stoll*[13] | 20 NRN sites, United States | 2003 to 2007 | 25/421 (6) | 226/871 (26) | 754/1370 (55) | 1079/1498 (72) | 2084/4160 (50) |
EPICure2[14] | United Kingdom; Ireland | 2006 | 3/152 (2) | 66/339 (19) | 178/441 (40) | 346/521 (66) | 593/1453 (40) |
Itabashi*[15] | Japan | 2005 | 33/97 (34) | 153/282 (54) | 324/423 (77) | 428/501 (85) | 938/1303 (72) |
Ishii*[16] | 20 NRN sites, Japan | 2003 to 2005 | 28/75 (37) | 158/245 (64) | 258/332 (78) | 347/405 (86) | 791/1057 (75) |
Tyson§[17] | 19 NRN sites, United States | 1998 to 2003 | (5) | (26) | (56) | (75) | 2267/4446 (51) |
Epibel*[18] | 19 perinatal centers in Belgium | 1999 to 2000 | 0/2 (0) | 1/18 (6) | 19/65 (29) | 50/90 (56) | 175/322 (54) |
NEPS1*[19] | Norway | 1999 to 2000 | 0/2 (0) | 9/23 (39) | 35/68 (60) | 55/69 (80) | 99/152 (65) |
EpipageΔ[20] | 9 regions in France | 1997 | 0/16 (0) | 0/30 (0) | 13/42 (31) | 59/119 (50) | 72/207 (35) |
EPICure1*[21] | United Kingdom; Ireland | 1995 | 2/22 (9) | 26/131 (20) | 100/298 (34) | 186/357 (52) | 314/811 (39) |
NICU: neonatal intensive care unit; NRN: Neonatal Research Network; ANS: antenatal steroid therapy; AT: active treatment.
* Survival of NICU admissions to discharge.
¶ Survival of live births to 1 year.
Δ Survival of live births including infants who died in the delivery room and were not admitted to the NICU.
◊ Survival of NICU admissions to 1 year.
§ Survival of NICU admissions until 18 to 22 months corrected age.